Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan Pawlak

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Diagnostic Microbiology and Infectious Disease|October 28, 2018
VISA-Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to TelavancinLouis D Saravolatz, Joan Pawlak
Jac-Antimicrobial Resistance|July 5, 2024
Rhodomyrtone: a new anti-<i>Staphylococcus aureus</i> agent against resistant strainsLouis D Saravolatz, Joan Pawlak
The Journal of Antimicrobial Chemotherapy|November 14, 2022
In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolidLouis D Saravolatz, Joan Pawlak
Antimicrobial Agents and Chemotherapy|April 21, 2010
In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolatesLouis Saravolatz, Joan Pawlak, Leonard Johnson
International Journal of Antimicrobial Agents|June 14, 2005
Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniaeLouis Saravolatz, Odette Manzor, Joan Pawlak, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2007
Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureusLouis D Saravolatz, Joan Pawlak, Leonard B Johnson
International Journal of Antimicrobial Agents|April 24, 2010
In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)Louis D Saravolatz, Joan Pawlak, Leonard B Johnson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2012
In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolatesLouis D Saravolatz, Joan Pawlak, Leonard B Johnson
Idcases|February 4, 2021
A case of <i>Gemella morbillorum</i> native valve endocarditis and results of <i>in vitro</i> susceptibility testingFarah Tanveer, Joan Pawlak, Dima Youssef, et al.
Infection Control and Hospital Epidemiology|September 29, 2006
Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal diseaseLeonard B Johnson, Anilrudh A Venugopal, Joan Pawlak, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Diagnostic Microbiology and Infectious Disease|October 28, 2018
VISA-Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to TelavancinLouis D Saravolatz, Joan Pawlak
Jac-Antimicrobial Resistance|July 5, 2024
Rhodomyrtone: a new anti-<i>Staphylococcus aureus</i> agent against resistant strainsLouis D Saravolatz, Joan Pawlak
The Journal of Antimicrobial Chemotherapy|November 14, 2022
In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolidLouis D Saravolatz, Joan Pawlak
Antimicrobial Agents and Chemotherapy|April 21, 2010
In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolatesLouis Saravolatz, Joan Pawlak, Leonard Johnson
International Journal of Antimicrobial Agents|June 14, 2005
Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniaeLouis Saravolatz, Odette Manzor, Joan Pawlak, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2007
Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureusLouis D Saravolatz, Joan Pawlak, Leonard B Johnson
International Journal of Antimicrobial Agents|April 24, 2010
In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)Louis D Saravolatz, Joan Pawlak, Leonard B Johnson
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2012
In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolatesLouis D Saravolatz, Joan Pawlak, Leonard B Johnson
Idcases|February 4, 2021
A case of <i>Gemella morbillorum</i> native valve endocarditis and results of <i>in vitro</i> susceptibility testingFarah Tanveer, Joan Pawlak, Dima Youssef, et al.
Infection Control and Hospital Epidemiology|September 29, 2006
Emergence of community-associated methicillin-resistant Staphylococcus aureus infection among patients with end-stage renal diseaseLeonard B Johnson, Anilrudh A Venugopal, Joan Pawlak, et al.
Pageof 3